

Pharmaceutical Sciences, 2025, 31(2), x-x doi:10.34172/PS.024.40508 https://ps.tbzmed.ac.ir/

Review Article



Exploring the Effect of Vitamin B12 on Febrile Seizures in Children: A Systematic Review and Meta-analysis of Case-control Studies

Navid Sherafati¹⁰, Hamid Abbasi^{2,3*10}, Sama Rahnemayan³¹⁰, Elahe Abdi Bastami⁴¹⁰, Sepehr Khosravi⁵¹⁰, Kiarash Tajernarenj²¹⁰, Sarvin Sanaie^{3*10}

¹Department of Nutrition, School of Health and Nutrition, Yasuj University of Medical Sciences, Yasuj, Iran.
 ²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
 ³Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
 ⁴Isfahan Neurosciences Research Center, Isfahan University of Medical sciences, Isfahan, Iran.
 ⁵Department of Neurology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Article Info

Article History: Received: 5 Jun 2024 Accepted: 14 Aug 2024 ePublished: 21 Jan 2025

Keywords:

-Children -Febrile seizure -Systematic review -Vitamin B12

Abstract

Background: Vitamin B12 (VB12) is a water-soluble vitamin, deficiency of which causes an extensive heterogeneous spectrum of neurological symptoms including vision disturbances, paresthesia, tremor, and seizure. The aim of this investigation is to determine the effect of serum VB12 levels on pediatric patients with febrile seizure (FS).

Methods: In this meta-analysis, case-control studies that evaluated the effect of serum VB12 levels in pediatric patients with FS were included. Web of Science, PubMed, Scopus, and Google Scholar were searched until August 13, 2024. The PICO criteria for this meta-analysis were as follows: Population/Patients (P: pediatric patients with febrile seizures); Issue of interest (I: serum levels of VB12); Comparison (C: control); Outcome (O: occurrence of febrile seizure). Quality assessment was assessed according to the Newcastle-Ottawa Scale (NOS) tool for case-control studies. The outcome assessment scales, study groups, and serum VB12 levels were extracted. *Results:* Of 435 initial articles, eventually 6 studies remained in the meta-analysis. Existing

evidence indicated that serum VB12 concentrations were insignificantly lower in FS patients than controls (WMD= -1.09 pg/ml; 95% CI: -2.23, 0.04; P= 0.06), although a significant between-study heterogeneity was observed (I^2 = 98.10%, P< 0.001).

Conclusion: The results of our study pointed out that there is low serum VB12 concentrations in FS patients compared with controls. Despite the fact, one of the best ways to prevent FS in children can be VB12 supplementation and proper diet therapy.

Introduction

Febrile seizure (FS) is the most prevalent seizure disturbance that is accompanied by fever (up to 38 centigrade) in children younger than 5 years old.^{1,2} FS is defined via the International League Against Epilepsy (ILAE) as absence of prior afebrile seizure history and any trauma, intoxication, electrolyte or metabolic impairment, or infection of the central nervous system.³ The prevalence rate of FS varies between countries, ranging from 2%-5% in the USA4-7 to Europe and 8%-11% in East Asia.8,9 Moreover, the combined prevalence of FS is 47.9% in Iran.¹⁰ Approximately 65-70 percent of all FS cases appear as simple FS (15 minutes or less) without lateralizing features such as intellectual disability and hemiplegia.^{1,11} The accurate etiopathogenesis of FS is yet unclear and considered to be multifactorial. Particularly certain genes may increase the risk of familial epilepsy syndromes that can lead to FS, immunologic repercussion, trace element

disturbances (i.e. selenium, iron, and zinc) and vitamin deficiencies (i.e. pyridoxine, folic acid, vitamin B6 and B12). 12,13

Various studies have investigated the effect of nutrients such as vitamins, zinc, iron, homocysteine, copper, magnesium, etc. on febrile seizure. Previously conducted meta-analysis has indicated that there are significant differences in zinc concentration between febrile seizure patients and the control group; while there is no significant difference in the concentration of copper, magnesium and selenium between these two groups.¹³ Jang *et al.*¹⁴ also showed in a study that serum iron deficiency was associated with an increased risk of febrile seizure, and therefore it is necessary to monitor the status of iron and even hemoglobin in children with this disease. Also, it has been determined that vitamin D level is lower in children with febrile seizure.¹⁵

Several studies have shown the preventive effects of

*Corresponding Authors: Hamid Abbasi, E-mail: h.abbasi@tbzmed.ac.ir & Sarvin Sanaie, E-mail: sarvin_so2000@yahoo.com ©2025 The Author(s). This is an open access article and applies the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.

serum vitamin B12 (VB12) in patients with FS.^{2,11,16-18} VB12 is a water-soluble vitamin that cannot be synthesized by the human body.^{19,20} VB12 deficiency is associated with inadequate dietary intake, which can lead to a wide range of heterogeneous neurological symptoms including lethargy, orthostatic hypotension, gastrointestinal motility disorder, stomatitis, tachycardia, visual disturbances, hyporeflexia, seizures, and tremors.²¹ One of the causes of nerve attack is hyperhomocysteinemia²² and VB12 is effective in its metabolism. VB12 is a cofactor in methylmalonyl coenzyme A (CoA) degradation and homocysteine (Hcy) remethylation.²³ On the other hand, VB12 together with folic acid plays a key role in the conversion of Hcy to methionine and with these mechanisms prevents hyperhomocysteinemia (Hhcy).^{20,24} However, the exact mechanism of neurological symptoms in VB12 deficiency is not fully understood and further studies should be conducted in this field.

Since VB12 levels children plays a significant role on the occurrence of febrile seizure, the present meta-analysis was conducted to collect and review the results of studies conducted in this field, and evaluate the relationship between serum VB12 levels and FS occurrence and its association with severity of clinical symptoms.

Methods

This systematic review and meta-analysis was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.²⁵

The search strategy of literature

Three online databases (Web of Science, PubMed and Scopus) and Google Scholar were searched independently (by H.A and N.SH) until August 13, 2024. Moreover, the reference lists of published researches were reviewed by 2 independent authors (N.SH and H.A) for avoiding missing data. The search strategy of scientific databases is described in Supplementary Material.

Eligibility criteria

Studies were included in this systematic review if they met at least one of the following criteria: (1) Evaluated the serum level of VB12 in FS patients; (2) Determined the relationship of serum VB12 levels with clinical symptoms; and (3) observational studies. Studies were excluded in the case of: (1) Non English studies; (2) Case reports or case series; (3) Letters, review articles and commentaries; (4) experimental studies; and (5) Conference abstracts.

Study selection

The eligible articles for this systematic review were differentiated by four investigators (N.SH, E.A.B, S.KH, K.T.N) based on titles and abstracts of the articles and above mentioned eligibility criteria. After screening studies based on their title and abstract in the first step, 4 researchers (N.SH, E.A.B, S.KH and H.A) checked the initially included studies by performing a precise screening

based on the full-text and excluded studies that didn't report appropriate quantitative data to be included in the systematic review.

Methodological quality assessment

Determining the quality of articles was done using the Newcastle-Ottawa Scale (NOS) critical appraisal tool by a researcher (H.A) and checked by another author (S.S). This tool is designed to assess the quality of observational studies encompassing case-control and cohort studies which has three domains containing selection (four questions), comparability (one question), and exposure (three questions) and its results range from 0 to 9.²⁶ Studies with a minimum score of 7 were considered as a good quality.

Data extraction

The acquired data was extracted independently by two researchers (N.SH, H.A) and checked by third researcher (S.S), afterwards, to insure accuracy and minimize bias. The publication year, country, outcome assessment scales, first author of the study and participants' characteristics (including age, number, health condition, serum levels of VB12) were extracted from the included studies. In case of missing data in the manuscript, corresponding author of the relevant article were contacted to solve the problem. The outcome assessment scales, study groups, summary of the results and conclusion of the systematic review were also extracted.

Data synthesis and statistical analysis

For statistical analysis, random-effects restricted maximum likelihood model was utilized to estimate the combined effect size. With using the I₂ index, between-study heterogeneity was evaluated. Indeed, I, index exceeding 50% was considered as a high heterogeneity.²⁷ To present the data, means ± standard deviation (S.D.) were used. In cases and controls which were reported variously were estimated via suitable statistical calculations. The effect size was reported as weighted mean difference (WMD) along with 95% confidence intervals (CIs). Subgroup meta-analysis was done to identify the sources of potential heterogeneity. For estimating the impact of each study on the pooled effect size of the meta-analysis, sensitivity analysis considering the Leave-one-out Method was performed. The funnel plot inspection with Begg's rank correlation and Egger's weighted regression tests were conducted to identify any publication bias.^{28,29} In cases of publication bias, Duval & Tweedie "trim and fill" analysis was performed. STATA version 16 (Stata Corporation, College Station, TX, US) was used for all statistical analyses with considering a significant level of p < 0.05.

Results

Study selection

In the present meta-analysis, 435 articles were identified during our initial search; 69 of which were removed due

to duplication. After screening the remaining 366 articles, 349 articles were excluded from the study after reviewing the title and abstract, and 17 articles entered the next stage for full-text review. From these articles, eight articles were excluded due to being case report.³⁰⁻³⁷ One study were excluded because they were based on animal models.³⁸ Also, in the study of Xiaoxue et al.39, although febrile seizure was mentioned, the main investigated outcome was the severity of autism in children. For this reason, they were excluded from the study.One study were excluded due to they assessed the cerebrospinal fluid level of vitamin B12.40 After excluding these studies, six case-control studies were examined in this meta-analysis. From these included studies, all cases measured the serum VB12 levels and investigated its relationship with febrile seizure.11,16,17,41-43 Other labortory findings that were examined in addition to serum VB12 levels in these studies included white bood cell (WBC) count, platelet (PLT) count, nucleated red blood cell (NRBC) count, mean corpuscular hemoglobin (MCH), iron, hematocrit (Hct), immunoglobulin (IG), vitamin D, selenium, zinc, ferritin, magnesium, red cell distribution width (RDW), hemoglobin and homocysteine, mean corpuscular volume (MCV) and Serum Folic Acid. The PRISMA flowchart of the included articles is shown in Figure 1.

Study characteristics

The specifications of the included studies are summarized in Table 1. The total number of participants in these six

studies was 772, placed in two groups: Case (n = 401) and control (n = 371). The control group in three included studies were healthy in terms of health status.^{11,17,42,43} In one study, control group had a febrile illness without seizure⁴¹ and in one study, control group had a fever without seizure.¹⁷ The average age of the participants in the included studies was 27.10 months, and the participants included both males and females. The studies were conducted in the years 2015 to 2023. Four studies were conducted in Turkey,^{11,16,17,42,43} one study was conducted in India.42 Three studies separately reported data for people with simple and complex febrile seizures. In all included studies, febrile seizure in the case group was diagnosed using the recorded data in the hospital; and to determine the serum VB12 levels, one study used the data recorded from the hospital,¹¹ one study used the immunoenzymatic assay method,¹⁶ and three studies used the immunoassay method.18,41,42

Result of quality assessment

As illustrated Table 2, the result of quality assessment was performed via NOS critical appraisal tool by a researcher (H.A) and checked by another author (S.S). Three studies have received the highest points They had representative cases and controls, adequate case definition, no history of disease in controls, community controls, secure record of exposure, adjustment for age and sex, same method of ascertainment for cases and controls, same rate of nonresponse for both groups, and pre-specified outcomes






Table 1. The characteristics and	main findings of the included studies.

			5					
Author, year	Design	Country	Sample size (case/ control)	Age, month (case/control)	Health con- dition (case/ control)	Outcome assessment scales	Serum vitamin B12 (pg/mL) (case/control)	p-value
Cigri <i>et</i> <i>al</i> . 2023	Case- control	Turkey	122 (61/61)	(35.36±13.91/ 35.54±13.87)	(FS/Fever with- out seizures)	PinAAcle 900 Z, SATURNO 300, CLIA, CBIA, AHA	(225±20.8/ 315±23.9)	<0.001
Aggar- wal <i>et</i> <i>al</i> . 2021	Case- control	India	70 (35/35)	NR	(FS/Febrile illness without seizures)	CLIA, SYSMEX KX-CC	(222±86.7/ 305±80.7)	<0.001
Turay <i>et al.</i> 2021	Case- control	Turkey	161 (97/64)	(21±12/26±14)	(FS/Healthy)	FBS	(373±176/ 527± 259)	<0.001
Özkale <i>et al.</i> 2015	Case- control	Turkey	179 (104/75)	(24.24/24.12)	(FS/Healthy)	FBS, CLMI, CMS	(453.2±206.0/ 521.9± 246.6)	0.08
Yüce <i>et</i> <i>al.</i> 2023	Case- control	Turkey	104 (50/54)	(21.6±11.6/ 20.5±11.2)	(FS/Healthy)	HABA, EIA	(401±175/ 441± 288)	<0.05
Aydın <i>et al.</i> 2021	Case- control	Turkey	136 (54/82)	(30.31±14.64/ 32.32±19.70)	(FS/Healthy)	NR	(316±205/ 419±208)	<0.05

pg: picograms, mL: milliliter, FS: Febrile Seizure, PinAAcle 900 Z: Perkin Elmer Atomic Absorption method, SATURNO 300: homogeneous colorimetric enzyme technique, CLIA: chemiluminescence immunoassay, CBIA: Competitive binding immunoenzymatic assay, AHA: Automatic hematological analyzer, SYSMEX KX-CC: SYSMEX KX-cell counter, FBS: fasting blood sample, CLMI: chemoluminescent microparticle immunoassay, CMS: chromatography-mass spectrometry, HABA: Hitachi 7600-020 automatic biochemical analyzer, EIA: electrochemiluminescence immunoassay analyzer.

and analyses.^{17,43,44} Additionally, Three publications have received the lowest points, demonstrating a moderate quality of the studies. They had potential for no adjustment for confounders, selection biases, some missing data, hospital controls, and no information on the characteristics or reasons of the missing data or the potential impact on the results.^{11,42,43} Details of evaluating with NOS critical appraisal tool of the papers are shown in Table 2.

Findings from the meta-analysis

Serum VB12 concentrations in FS and control subjects

The results of this meta-analysis have indicated that serum VB12 concentrations were insignificantly lower in FS patients than controls (WMD= -1.09 pg/ml; 95% CI: -2.23, 0.04; P= 0.06) (Figure 2), although a significant between-study heterogeneity was observed (I^2 = 98.10%, P< 0.001).

To find the potential source of heterogeneity, subgroup

 Table 2. Quality assessment of the included articles based on NOS critical appraisal tool.

Study	Quality assesment items									
Study	Selection	Comparability	Exposure							
Cigri et al.	****	**	***							
Aggarwal et al.	**	*	**							
Turay et al.	**	*	**							
Özkale et al.	****	**	***							
Yüce et al.	**	*	**							
Aydin et al.	****	**	***							

analysis was performed. Subgrouping indicated that age and quality score could be probable sources of heterogeneity (Figure 3). Also sub-group analyses of studies based on their quality assessment scores revealed that in studies with quality score higher than 7, serum VB12 concentrations were insignificantly lower in FS patients than controls (WMD= -0.61 pg/ml; 95% CI: -1.07, -0.15; P= 0.02) (Figure 4). The results of sub-group analyses based on sample size and country of origin have been summarized in Figure 5 and Figure 6, respectively.

The evidence of probable publication bias was observed (Egger's (P<0.05) and Begg's tests (P=0.09), however, publication bias analysis demonstrated that the shape of funnel plot was asymmetric (Figure 7). In accordance to that, trim and fill analysis was performed with 5 studies (WMD= -1.09 pg/mL; 95% CI: -2.23, 0.04; P>0.05).

Discussion

In this current meta-analysis, utilizing case-control studies data, we evaluated the serum VB12 concentrations in both FS patients and controls. The limited accessible evidence suggested low levels of serum VB12 may be a risk factor for febrile seizure in children.^{11,16,17,41-43} Remarkably, The results of our meta-analysis indicated that those in the FS groups had 1.09 pg/ml lower VB12 concentrations compared with those in the control groups.

VB12 is a water-soluble vitamin that cannot be synthesized in human body^{20,21} and is taken from the diet. Animal foods are the only dietary sources of VB12.⁴⁵

Vitamin B12 and	Febrile Seizures	s in Children
-----------------	------------------	---------------

	٦	Freatme	nt		Contr	ol				WMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD				with 95% CI	(%)
Cigri et al. 2023	61	225	20.8	61	315	23.9				-3.99 [-4.60, -3.38]	16.25
Aggarwal et al. 2021	35	222	86.7	35	305	80.7		-	-	-0.98 [-1.47, -0.49]	16.53
Turay et al. 2021	97	373	176	64	527	259			-	-0.72 [-1.04, -0.40]	16.83
Özkale et al. 2015	104	453.2	206	75	521.9	246.6			-	-0.31 [-0.60, -0.01]	16.86
Yüce et al. 2023	50	401	175	54	441	288			-	-0.17 [-0.55, 0.22]	16.74
Aydin et al. 2021	54	316	205	82	419	208				-0.50 [-0.84, -0.15]	16.79
Overall										-1.09 [-2.23, 0.04]	
Heterogeneity: $\tau^2 = 1.9$	96, I ² :	= 98.10	%, H ²	= 52	.73						
Test of $\theta_i = \theta_j$: Q(5) = 1	27.81	, p = 0.	00								
Test of $\theta = 0$: $z = -1.89$), p = (0.06									
							-4	-2	0		

Random-effects REML model

Figure 2. Weighted mean difference (WMD) with 95% confidence interval (CI) of the comparison of serum VB12 concentrations in FS patients and controls.

	1	Treatme	nt		Contr	ol	WMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD	with 95% Cl	(%)
24≤								
Cigri et al. 2023	61	225	20.8	61	315	23.9	-3.99 [-4.60, -3.38]	16.25
Özkale et al. 2015	104	453.2	206	75	521.9	246.6	-0.31 [-0.60, -0.01]	16.86
Aydin et al. 2021	54	316	205	82	419	208		16.79
Heterogeneity: $r^2 = 4$.	21, I ² =	= 99.079	%, H ² :	= 10	7.27		-1. 58 [-3.92, 0.75]	
Test of $\theta_i = \theta_j$: Q(2) =	117.87	, p = 0.0	00					
Test of $\theta = 0$: z = -1.33	3, p = (0.18						
<24								
Turay et al. 2021	97	373	176	64	527	259	-0.72 [-1.04, -0.40]	16.83
Yüce et al. 2023	50	401	175	54	441	288		16.74
Heterogeneity: $\tau^2 = 0$.	12, I ² =	= 78.789	%, H ² :	= 4.7	1		-0.45 [-1.00, 0.09]	
Test of $\theta_i = \theta_j$: Q(1) =	4.71, p	0 = 0.03						
Test of $\theta = 0$: $z = -1.63$	3, p = 0	0.10						
NR								
Aggarwal et al. 2021	35	222	86.7	35	305	80.7	-0.98 [-1.47, -0.49]	16.53
Heterogeneity: $r^2 = 0$.	00, I ² =	= .%, H ²	= .				-0.98 [-1.47, -0.49]	
Test of $\theta_i = \theta_j$: Q(0) =	0.00, p) = .						
Test of $\theta = 0$: $z = -3.9$	1, p = (0.00						
Overall							-1.09 [-2.23, 0.04]	
Heterogeneity: $\tau^2 = 1$.	96, I ² =	= 98.109	%, H ² :	= 52.	73			
Test of $\theta_i = \theta_j$: Q(5) =	127.81	p = 0.0	00					
Test of $\theta = 0$: $z = -1.8$	9, p = (0.06						
Test of group different	ces: Q	b(2) = 2.	48, p	= 0.2	9		-4 -2 0	
andom-effects REML	mode							

Figure 3. Weighted mean difference (WMD) with 95% confidence interval (CI) of the sub-group analyses on comparison of serum VB12 concentrations in FS patients and controls based on participants' age.

		Treatme	ent		Contr	ol	WMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD	with 95% Cl	(%)
7>								
Aggarwal et al. 2021	35	222	86.7	35	305	80.7	-0.98 [-1.47, -0	.49] 16.53
Turay et al. 2021	97	373	176	64	527	259		.40] 16.83
Yüce et al. 2023	50	401	175	54	441	288		.22] 16.74
Heterogeneity: $\tau^2 = 0$.	12, I ²	= 75.42	%, H ²	= 4.0	07		-0.61 [-1.07, -0	.15]
Test of $\theta_i = \theta_j$: Q(2) =	7.79, p	0.02						
Test of θ = 0: z = -2.60	0, p =	0.01						
7≤								
Cigri et al. 2023	61	225	20.8	61	315	23.9	-3.99 [-4.60, -3	.38] 16.25
Özkale et al. 2015	104	453.2	206	75	521.9	246.6		.01] 16.86
Aydin et al. 2021	54	316	205	82	419	208		.15] 16.79
Heterogeneity: $\tau^2 = 4$.	21, I ²	= 99.07	%, H ²	= 10	7.27		-1.58 [-3.92, 0	.75]
Test of $\theta_i = \theta_j$: Q(2) =	117.87	, p = 0.	00					
Test of θ = 0: z = -1.33	3, p =	0.18						
Overall							-1.09 [-2.23, 0	.04]
Heterogeneity: $\tau^2 = 1$.	96, I ²	= 98.10	%, H ²	= 52	.73			
Test of $\theta_i = \theta_j$: Q(5) =	127.81	, p = 0.	00					
Test of $\theta = 0$: $z = -1.89$	9, p =	0.06						
Test of group difference	ces: Q	_b (1) = 0	. <mark>65</mark> , p	= 0.4	12		- <u>, , , , , , , , , , , , , , , , , , , </u>	
							-4 -2 0	

Random-effects REML model

Figure 4. Weighted mean difference (WMD) with 95% confidence interval (CI) of the sub-group analyses on comparison of serum VB12 concentrations in FS patients and controls based on quality assessment scores.

		Treatme	nt		Contr	rol				WMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD				with 95% CI	(%)
>110 subjects											
Cigri et al. 2023	61	225	20.8	61	315	23.9				-3.99 [-4.60, -3.38]	16.25
Turay et al. 2021	97	373	176	64	527	259			-	-0.72 [-1.04, -0.40]	16.83
Özkale et al. 2015	104	453.2	206	75	521.9	246.6			-	-0.31 [-0.60, -0.01]	16.86
Aydin et al. 2021	54	316	205	82	419	208				-0.50 [-0.84, -0.15]	16.79
Heterogeneity: $\tau^2 = 2$.	95, I ²	= 98.84	%, H ²	= 86	.24					-1.36 [-3.06, 0.33]	
Test of $\theta_i = \theta_j$: Q(3) =	118.11	, p = 0.0	00								
Test of $\theta = 0$: $z = -1.5$	8, p =	0.12									
≤110 subjects											
Aggarwal et al. 2021	35	222	86.7	35	305	80.7			-	-0.98 [-1.47, -0.49]	16.53
Yüce et al. 2023	50	401	175	54	441	288			-	-0.17 [-0.55, 0.22]	16.74
Heterogeneity: $\tau^2 = 0$.	28, I ²	= 84.82	%, H ²	= 6.5	59					-0.56 [-1.36, 0.24]	
Test of $\theta_i = \theta_j$: Q(1) =	6.59, p	0 = 0.01									
Test of $\theta = 0$: $z = -1.3$	7, p =	0.17									
Overall								-		-1.09 [-2.23, 0.04]	
Heterogeneity: $\tau^2 = 1$.	96, I ²	= 98.10	%, H ²	= 52	.73						
Test of $\theta_i = \theta_j$: Q(5) =	127.8	1, p = 0.	00								
Test of $\theta = 0$: $z = -1.8$	9, p =	0.06									
Test of group difference	ces: Q	_b (1) = 0	.71, p	= 0.4	40					-	
							-4	-2	()	

Random-effects REML model

Figure 5. Weighted mean difference (WMD) with 95% confidence interval (CI) of the sub-group analyses on comparison of serum VB12 concentrations in FS patients and controls based on study sample size.

		Treatme	ent		Cont	rol				WMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD				with 95% CI	(%)
India											
Aggarwal et al. 2021	35	222	86.7	35	305	80.7		-	-	-0.98 [-1.47, -0.49]	16.53
Heterogeneity: $\tau^2 = 0$.	.00, I ²	= .%, H	2 = .					-		-0.98 [-1.47, -0.49]	
Test of $\theta_i = \theta_j$: Q(0) =	0.00, p) = .									
Test of $\theta = 0$: $z = -3.9$	1, p =	0.00									
Turkey											
Cigri et al. 2023	61	225	20.8	61	315	23.9	-			-3.99 [-4.60, -3.38]	16.25
Turay et al. 2021	97	373	176	64	527	259		-	-	-0.72 [-1.04, -0.40]	16.83
Özkale et al. 2015	104	453.2	206	75	521.9	246.6			-	-0.31 [-0.60, -0.01]	16.86
Yüce et al. 2023	50	401	175	54	441	288			-	0.17 [-0.55, 0.22]	16.74
Aydin et al. 2021	54	316	205	82	419	208				-0.50 [-0.84, -0.15]	16.79
Heterogeneity: $\tau^2 = 2$.	.47, I ²	= 98.61	%, H ²	= 71	.72					-1.12 [-2.51, 0.27]	
Test of $\theta_i = \theta_j$: Q(4) =	126.49	9, p = 0.	00								
Test of $\theta = 0$: $z = -1.5$	8, p =	0.11									
Overall										-1.09 [-2.23, 0.04]	
Heterogeneity: $\tau^2 = 1$.	.96, I ²	= 98.10	%, H ²	= 52	.73						
Test of $\theta_i = \theta_j$: Q(5) =	127.81	l, p = 0.	00								
Test of $\theta = 0$: $z = -1.8$	9, p =	0.06									
Test of group differen	ces: Q	_b (1) = 0	.03, p	= 0.8	35						
							-4	-2	0		

Random-effects REML model

Figure 6. Weighted mean difference (WMD) with 95% confidence interval (CI) of the sub-group analyses on comparison of serum VB12 concentrations in FS patients and controls based on country of origin.




Figure 7. Funnel plot for publication bias.

VB12 deficiency may occurre in children due to the impairment in the transport and metabolism of VB12, its low dietary consumption, or abnormal absorption.⁴⁶ One of the possible mechanisms of low serum VB12 levels is associated with the conversion of methylmalonyl CoA to succinyl CoA which cannot occure in children with VB12 deficiency and causes fatty acids to be synthesized through the accumulation of methylmalonyl CoA. The adverse effect of this process is myelin synthesis disturbances in the central nervous system, which affects cognitive performance and neurodevelopment of children.⁴⁷ Low serum VB12 can decrease seizure threshold in children

which may serve as a probable risk factor for FS.18

Low levels of serum VB12 appear to be a trigger for seizures, but its exact mechanism of action is unclear.¹⁹ Several case-control studies have evaluated the association between VB12 deficiency and febrile seizures in pediatric patients. Çiğrı *et al.*¹⁶ showed that the serum level of VB12 in FS patients was significantly lower in comparison to the children with only fever onset. It is noteworthy that in this study, in addition to the level of VB12, level of other minerals, such as zinc, vitamin D, selenium, etc., were examined, among which, the level of VB12 showed a significant difference between the study group and the control group. Yüce *et al.*⁴² investigated the level of VB12 in febrile convulsions in a study and pointed out that the serum VB12 levels in children with febrile seizures was significantly lower than in the control group.

Ozkale *et al.*¹⁷ showed that the serum level of VB12 was significantly lower in children with febrile seizures compared to the control group. Turay *et al.*⁴⁸ also investigated the relationship between the serum level of VB12, folate, and iron on febrile seizure and reported that the level of VB12 has significant effects on FS in children. The result of the study of Aggarwal *et al.*² was also consistent with the study of Turay *et al.*⁴⁸ All the studies reviewed in this systematic study state that the level of VB12 is probably effective on febrile seizure and its incidence, however for more certainty, more quality studies with a

Sherafati, et al.

Table 3. Subgroup analyses of comparison of serun	n VB12 concentrations in FS patients and controls.
---	--

Group	Effect size (number)	WMD (95% CI)	P-within	l²(%)	P-heterogeneity
Total	6	-1.09 (-2.23, 0.04)	0.06	98.10	<0.001
Sample size (subjects)					
>110	4	-1.36 (-3.06, 0.33)	0.12	98.84	<0.001
≤110	2	-0.56 (-1.36, 0.24)	0.17	84.82	0.01
Quality score					
7≤	3	-1.58 (-3.92, 0.75)	0.18	99.07	<0.001
<7	3	-0.61 (-1.07, -0.15)	0.01	75.42	0.02
Country					
Turkey	5	-1.12 (-2.51, 0.27)	0.11	98.61	<0.001
India	1	-0.98 (-1.47, -0.49)	<0.001	-	-
Age (months)					
24≤	3	-1.58 (-3.92, 0.75)	0.18	99.07	<0.001
<24	2	-0.45 (-1.00, 0.09)	0.1	78.78	0.03
NR	1	-0.98 (-1.47, -0.49)	< 0.001	-	-

WMD: weighted mean difference; NR: not reported

larger population and less bias are needed.^{2,16-18,48}

The study analyzed the link between serum vitamin B12 (VB12) levels and febrile seizures (FS) in children through a meta-analysis of five case-control studies. Results showed that VB12 levels were lower in FS patients compared to controls, though the difference was not statistically significant. This suggests a possible trend but not a definitive link between VB12 deficiency and FS. The findings align with other research indicating nutritional deficiencies, such as zinc and iron, may play a role in FS. Future research should include larger, more diverse cohorts, longitudinal studies, and comprehensive nutritional assessments to better understand this relationship. Mechanistic studies and intervention trials could elucidate the biological pathways involved and potential benefits of VB12 supplementation in preventing FS.

This present study is the first meta-analysis which evaluates the link between VB12 and FS in children. This is an essential affair to acknowledge potential limitations in this study. The original restriction of this study were the limited number of well-designed case-control studies and only included 772 participants. Therefore, conducting more studies in this respect to achieve higher number of participants will improve the power of study. Furthermore, 5 studies out of overall included 6 studies in this metaanalysis have been conducted in Turkey, which may impact the generalizability of these findings regarding the impact of genetic or ethnic factors on the results, and further studies in other regions of the world are needed to have a better general understanding of this topic and establish a causal relationship. Additionally, the original strength of this meta-analysis includes comprehensive coverage of the published literature and study design guided by PRISMA.

Conclusion

Consequently, we found low serum levels of VB12 in FS patients in compared with control groups. To prevent FS in children, it seems that the best way in these patients is to properly evaluate children in terms of lack of nutrients, including VB12, zinc, folate, and iron, as well as supplement

therapy with these substances and a suitable diet.

Ethics Issues

The ethics committee of the Tabriz University of Medical Science reviewed and approved the study protocol (Ethical Code: IR.TBZMED.VCR.REC.1402.179).

Acknowledgments

The research protocol was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number 72749).

Author Contributions

Navid Sherafati: Investigation, Methodology, Visualization, Validation, Writing - Original Draft. Hamid Abbasi: Conceptualization, Investigation, Methodology, Formal Analysis, Data curation, Supervision, Visualization, Validation, Writing - Original Draft. Sama Rahnemayan: Methodology, Visualization, Validation, Writing - Original Draft. Elahe Abdi Bastami: Methodology. Sepehr Khosravi: Methodology. Kiarash Tajernarenj: Investigation, Conceptualization, Methodology. Sarvin Sanaie: Supervision, Writing - Review & Editing.

Conflict of Interest

The authors declare no conflicts of interest.

Supplementary Data

Supplementary data are available at https://doi. org/10.34172/PS.024.40508.

References

- Pediatrics AAo. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127(2):389-94. doi:10.1542/peds.2010-3318
- Aggarwal S, Abrol P, Karunanand B, Suri A. Role of vitamin B12 and folic acid deficiency as risk factors in pediatric patients of febrile seizures in a tertiary care centre. Indian J Basic Appl Med Res. 2021;10(2):158-66. doi:10.36848/IJBAMR/2020/26215.55642

- Epidemiology Co, Prognosis ILAE. Guidelines for epidemiologic studies on epilepsy. Epilepsia. 1993;34(4):592-6. doi:10.1111/j.1528-1157.1993. tb00433.x
- Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. New Eng J of Med. 1976;295(19):1029-33. doi:10.1056/ NEJM197611042951901
- Vestergaard M, Wisborg K, Henriksen TB, Secher NJ, Østergaard JR, Olsen J. Prenatal exposure to cigarettes, alcohol, and coffee and the risk for febrile seizures. Pediatrics. 2005;116(5):1089-94. doi:10.1542/ peds.2004-2210
- Canpolat M, Per H, Gumus H, Elmali F, Kumandas S. Investigating the prevalence of febrile convulsion in Kayseri, Turkey: An assessment of the risk factors for recurrence of febrile convulsion and for development of epilepsy. Seizure. 2018;55:36-47. doi:10.1016/j. seizure.2018.01.007
- Verity C, Butler N, Golding J. Febrile convulsions in a national cohort followed up from birth. II--Medical history and intellectual ability at 5 years of age. Br Med J. 1985;290(6478):1311-5. doi:10.1136/ bmj.290.6478.1311
- Tsuboi T. Epidemiology of febrile and afebrile convulsions in children in Japan. Neurology. 1984;34(2):175-81. doi:10.1212/WNL.34.2.175
- Choi YJ, Jung JY, Kim JH, Kwon H, Park JW, Kwak YH, et al. Febrile seizures: Are they truly benign? Longitudinal analysis of risk factors and future risk of afebrile epileptic seizure based on the national sample cohort in South Korea, 2002–2013. Seizure. 2019;64:77-83. doi:10.1016/j.seizure.2018.12.004
- 10. Delpisheh A, Veisani Y, Sayehmiri K, Fayyazi A. Febrile seizures: etiology, prevalence, and geographical variation. Iran J of Child Neurol. 2014;8(3):30-7.
- Turay S, Hanci F, Ozde S. An overview of vitamin B12 and iron deficiencies as a risk factors in children with febrile seizure etiology. Experi Biomedical Res. 2021;4(2):154-63. doi:10.30714/j-ebr.2021267979
- 12. Thébault-Dagher F, Herba CM, Séguin JR, Muckle G, Lupien SJ, Carmant L, et al. Age at first febrile seizure correlates with perinatal maternal emotional symptoms. Epilepsy Res. 2017;135:95-101. doi:10.1016/j.eplepsyres.2017.06.001
- Saghazadeh A, Mahmoudi M, Meysamie A, Gharedaghi M, Zamponi GW, Rezaei N. Possible role of trace elements in epilepsy and febrile seizures: a meta-analysis. Nutr rev. 2015;73(11):760-79. doi:10.1093/nutrit/nuv026
- Jang HN, Yoon HS, Lee EH. Prospective case control study of iron deficiency and the risk of febrile seizures in children in South Korea. BMC Pediatr. Sep 4 2019;19(1):309. doi:10.1186/s12887-019-1675-4
- 15. Heydarian F, Bakhtiari E, Golmakani H, Fakhr Ghasemi N, Heidarian M. Serum Level of Vitamin D and Febrile Seizure? A Clinical Study. Iran J Child

Neurol. 2020;14(3):77-82.

- 16. Çığrı E, İnan FÇ. Comparison of serum selenium, homocysteine, zinc, and vitamin D levels in febrile children with and without febrile seizures: a prospective single-center study. Children. 2023;10(3):528. doi:10.3390/children10030528
- 17. Özkale Y, Erol İ, Kılıçarslan B, et al. Serum vitamin B12, folic acid, and homocysteine levels in children with febrile seizure. Turk J Pediatr. 2015;57(4):345-52.
- Osifo BO, Lukanmbi FA, Familusi JB. Cerebrospinal fluid folate and cobalamin levels in febrile convulsion. J Neurol Sci. 1985;68(2-3):185-90. doi:10.1016/0022-510x(85)90099-1
- Serin HM, Arslan EA. Neurological symptoms of vitamin B12 deficiency: analysis of pediatric patients. Acta Clini Croat. 2019;58(2):295. doi:10.20471/ acc.2019.58.02.13
- Taşkesen M, Yaramiş A, Katar S, Pirinççioğlu AG, Söker M. Neurological presentations of nutritional vitamin B12 deficiency in 42 breastfed infants in Southeast Turkey. Turk J of Med Sci. 2011;41(6):1091-6. doi:10.3906/sag-1009-1137
- Demir N, Koc A, Üstyol L, Peker E, Abuhandan M. Clinical and neurological findings of severe vitamin B12 deficiency in infancy and importance of early diagnosis and treatment. J of paed and child health. 2013;49(10):820-4. doi:10.1111/jpc.12292
- 22. Attilakos A, Papakonstantinou E, Schulpis K, et al. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res. 2006;71(2-3):229-32. doi:10.1016/j.eplepsyres.2006.06.015
- Graham SM, Arvela OM, Wise GA. Long-term neurologic consequences of nutritional vitamin B12 deficiency in infants. J Pediatr. 1992;121(5):710-4. doi:10.1016/S0022-3476(05)81897-9
- 24. Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5(11):949-60. doi:10.1016/S1474-4422(06)70598-1
- 25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]. Rev Panam Salud Publica. 2022;46:e112. Portuguese. doi:10.26633/RPSP.2022.112.
- 26. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5. doi:10.1007/s10654-010-9491-z.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
- 28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics.

1994:1088-101. doi:10.2307/2533446

- 29. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. doi:10.1136/ bmj.315.7109.629
- Matsumoto A, Shiga Y, Shimizu H, Kimura I, Hisanaga K. [Encephalomyelopathy due to vitamin B12 deficiency with seizures as a predominant symptom]. Rinsho Shinkeigaku. 2009;49(4):179-85. Japanese. doi:10.5692/clinicalneurol.49.179
- Aguglia U, Gambardella A, Oliveri RL, De Sarro G, Zappia M, Quattrone A. De novo epileptic confusional status in a patient with cobalamin deficiency. Metab Brain Dis. 1995;10(3):233-8. doi:10.1007/BF02081028
- Ch R, Iff S, Stucki A, Donati F, Stanga Z. 69-yearold patient with seizure of unknown origin. Praxis. 2007;96(10):383-5. doi:10.1024/1661-8157.96.10.383
- Riediger Ch, Iff S, Stucki A, Donati F, Stanga Z. 69-jährige Patientin mit unklarem zerebralen Krampfanfall [69-year-old patient with seizure of unknown origin]. Praxis (Bern 1994). 2007;96(10):383-5. German. doi:10.1024/1661-8157.96.10.383
- Myers KA, Dudley RW, Srour M. Hemiconvulsion-Hemiplegia-Epilepsy in a girl with cobalamin C deficiency. Epileptic Disord. 2018;20(6):545-50. doi:10.1684/epd.2018.1017
- 35. Olgac A, Yildiz E, Yilmaz A, Kasapkara CS, Ceylaner S, Alioglu B. A Delayed Presentation of Arginase Deficiency Presenting with Status Epilepticus. J Coll Physicians Surg Pak. 2022;32(12):1629-31. doi:10.29271/jcpsp.2022.12.1629
- Okoli S, Jenkins KA, Bojanowski CM. Current intensive care management of thrombotic thrombocytopenic purpura: a case report and updated literature review. J Intensive Care Med. 2023;38(7):592-7. doi:10.1177/08850666231171907
- Kanaya Y, Neshige S, Takemaru M, Shiga Y, Takeshima S, Kuriyama M. [Cerebral venous sinus thrombosis associated with hyperhomocysteinemia due to combined deficiencies of folate and vitamin B12]. Rinsho Shinkeigaku. 2016;56(2):116-9. Japanese. doi:10.5692/clinicalneurol.cn-000819
- 38. Hutchins D, Ball P. Circadian rhythms of folate and

vitamin B12 concentration in relation to convulsive thresholds of mice. Neurochem Intern. 1983;5(4):421-7. doi:10.1016/0197-0186(83)90071-2

- Xiaoxue L. Correlation between 5-HT, Hcy and the incidence and severity of autism in children. Cell Mol Biol (Noisy-le-grand). 2023;69(1):54-60. doi:10.14715/ cmb/2022.69.1.10
- Osifo BO, Lukanmbi FA, Familusi JB. Cerebrospinal fluid folate and cobalamin levels in febrile convulsion. J Neurol Sci. 1985;68(2-3):185-90. doi:10.1016/0022-510x(85)90099-1
- 41. Özkale Y, Erol İ, Kılıçarslan B, Özkale M, Saygı S, Sarıtürk Ç, Sezgin N. Serum vitamin B12, folic acid, and homocysteine levels in children with febrile seizure. Turk J Pediatr. 2015;57(4):345-52.
- Yüce O, Köle MT, Erol M, Somuncu HS, Özel A, Büke Ö. Serum Vitamin B12 Level of Children and Its Clinical Relationship with Febrile Seizures. 2023;8(4):349-54. doi:.4274/BMB.galenos.2023.2023-06-057
- Aydın H, Bucak İ, Bucak İH. Comparison of laboratory parameters between children with and without febrile convulsion. J Surg Med. 2021;5(2):149-52. doi:10.28982/josam.740090
- 44. Özkale Y, Erol İ, Kılıçarslan B, Özkale M, Saygı S, Sarıtürk Ç, et al. Serum vitamin B12, folic acid, and homocysteine levels in children with febrile seizure. Turk J Pediatr. 2015;57(4):345-52.
- Miller A, Korem M, Almog R, Galboiz Y. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. J Neurol Sci. 2005;233(1-2):93-7. doi:10.1016/j.jns.2005.03.009
- Rasmussen SA, Fernhoff PM, Scanlon KS. Vitamin B12 deficiency in children and adolescents. The J Pediatr. 2001;138(1):10-7. doi:10.1067/mpd.2001.112160
- Allen LH, Rosado JL, Casterline JE, et al. Vitamin B-12 deficiency and malabsorption are highly prevalent in rural Mexican communities. Am J Clin Nutr. 1995;62(5):1013-9. doi:10.1093/ajcn/62.5.1013
- Turay S, Hanci F, Ozde S. An overview of vitamin B12 and iron deficiencies as a risk factors in children with febrile seizure etiology. Exp Biomed Res. 2021;4(2):154-63. doi:10.30714/j-ebr.2021267979